Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed GI cancer such as esophagus, stomach, bile duct, pancreas, colon, or a likely GI origin, and it is not removable or has spread to other organs
- Your tumor must test HER2-positive (specific lab results like IHC 3+ or IHC 2+ with ISH) according to the trial rules
- You must have already had at least one treatment that targets HER2 for advanced disease, with treatment completed at least 2 weeks before starting (for stomach/esophagus cancers)
- You must be an adult (18+) and well enough to do daily activities (ECOG 0–2)
- Blood tests and organ function must meet safety limits (including enough white blood cells, platelets, hemoglobin, and acceptable liver/kidney function)
- You must be able to take oral pills by mouth, and you must agree to sign consent forms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This study tests a daily pill called neratinib for people with advanced cancers that have a change in the HER2 gene. It may help treat tumors that are no longer responding to other treatments.
This trial tests a combination pill (nilatinib maleate) and chemotherapy (capecitabine) for people with HER2-positive stomach or esophageal cancer that has spread to the brain. The goal is to see if this combo can shrink tumors and control the disease.
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.